Artificial intelligence (AI) is revolutionizing the pharmaceutical landscape, promising accelerated trial design and enhanced drug discovery. The market for AI in pharma is expected to grow by over 40% annually until 2030, underscoring its potential impact.
However, for US drug developers, navigating the regulatory landscape in Europe poses significant challenges. European health authorities are tightening their demands on how companies train AI algorithms, safeguard patient data, and validate the reliability of clinical evidence generated by these systems.
As major US biopharmaceutical companies conduct clinical trials in Europe, staying abreast of these regulatory changes is essential. Here’s a roadmap for US compliance and R&D teams to build AI pipelines that align with European regulations without delaying trial launches.
Understanding European Regulations: A Complex Framework
The EU AI Act, which comes into effect in August 2024, categorizes AI tools according to their risk levels. For pharmaceutical developers, any AI system employed to screen patients, suggest treatment protocols, or identify safety concerns within a trial will likely be classified as high-risk.
This classification entails rigorous obligations prior to trial initiation. Companies must compile exhaustive technical documentation, establish quality management systems, conduct conformity assessments, ensure human oversight, and register their systems in the EU database.
In addition to the AI Act, there are three other regulatory layers to consider:
Consequently, a single AI system may be subject to the AI Act, the Medical Device Regulation (MDR), the General Data Protection Regulation (GDPR), and guidance from the European Medicines Agency (EMA), each imposing unique and sometimes overlapping obligations.
US teams deploying AI in European trials encounter three primary operational challenges:
The EMA requires trial sponsors to provide a detailed explanation of how their AI models function. Before commencing a trial, sponsors must demonstrate the sources of training data, validate datasets for bias, elucidate model outputs, maintain controls for human intervention, and monitor performance over time. Ultimately, the trial sponsor, not the algorithm, is held legally and ethically accountable.
Under the GDPR, establishing a clear legal justification for processing clinical data can be problematic. Often, relying on consent according to Article 6(1)(a) creates a ‘double consent requirement’ alongside standard trial participation consent. The forthcoming EU Biotech Act (set for December 2025) aims to rectify this by shifting the legal basis to compliance with a legal obligation (Article 6(1)(c)), supported by public interest provisions under Article 9(2)(i) GDPR. This would simplify the consent process for trial teams.
Synthetic data serves a dual purpose: it helps overcome the quantitative limitations of clinical datasets while facilitating AI model development, all while minimizing the use of actual personal data. Both the EMA Reflection Paper and the AI Act acknowledge synthetic data as a valuable data augmentation technique. However, models trained on datasets that do not meet EU standards for representativeness and bias will be rejected. A Data Protection Impact Assessment (DPIA) must be conducted prior to any large-scale health data processing for AI training.
Local Privacy Variations: Design for Divergence
Since 2018, interpretations of the GDPR by European regulators, data authorities, and ethics boards have varied significantly. Moreover, EU laws allow member states to impose additional restrictions on sensitive health data, creating a complicated mosaic of local regulations.
The proposed Biotech Act, expected to be adopted in 2027, aims to prevent individual countries from adding extra data or consent requirements under the EU Clinical Trials Regulation (CTR), thus eliminating the need for country-specific legal reviews. However, until this Act is enacted, local regulatory checks remain crucial, and pharmaceutical companies that incorporate them into their trial protocols from the outset will avoid costly delays.
Strategic Priorities for US R&D and Compliance Teams
To maintain trial momentum while adhering to European standards, leadership teams should focus on six key priorities:
- AI Risk Classification from the Start
Conducting an AI risk classification exercise early in the process is essential. This should evaluate whether the tool is classified as high-risk under the EU AI Act, what data it processes, and which obligations apply at each regulatory level. - GxP-Aligned AI Governance
Structuring AI development within Good Practice (GxP) frameworks from the beginning will facilitate smoother compliance with EU requirements. This involves implementing version control, comprehensive model documentation, clear validation criteria, formal change control procedures, and thorough audit trails of AI decisions. -
Implement a DPIA Program
Every US pharmaceutical company utilizing AI systems to handle health or genetic data in Europe should establish a formal DPIA program. This program should address the nature and scope of data processing, data provenance, risks of automated decision-making, and technical and organizational mitigations. -
Engage Early with Regulatory Authorities
The draft Biotech Act allows for the designation of strategic biotech projects, providing access to regulatory sandboxes where teams can develop and test AI tools under defined EU rules. Engaging with regulatory authorities early can offer clarity and direction. -
Leverage Data Reuse Provisions
The EDPB Guidelines affirm that secondary research benefits from compatibility presumption under GDPR, and the draft Biotech Act permits data reuse across trials by the same controller. US pharma companies should proactively structure data agreements to take advantage of this framework. -
Create an Integrated Compliance Framework
The best approach to navigating Europe’s regulatory landscape is to integrate compliance efforts across all four regulatory layers. Mapping the GDPR, AI Act, EHDS, and sector-specific regulations against each AI system will clarify ownership and compliance responsibilities throughout the development lifecycle.
The Evolving Regulatory Landscape
The regulatory framework governing AI in pharma continues to evolve. Upcoming developments, including the final adoption of the EDPB Guidelines on scientific research and the anticipated approval of Guidelines on anonymization, will shape the landscape. As the European Health Data Space (EHDS) takes form and reliance on federated research infrastructure increases, the proposed Biotech Act will address critical legal gaps, establishing a clear framework for GDPR-compliant AI in pharmaceuticals.
Embracing Regulatory Preparedness
While the demands of European AI regulations can be daunting, they also present an opportunity for US drugmakers to elevate their standards. The January 2026 EMA-FDA joint Guiding Principles signify that transatlantic regulators are striving for alignment.
Rather than viewing European regulations as obstacles, US pharmaceutical companies should embrace them as quality benchmarks. Investing in transparent, compliant, and well-documented AI pipelines will provide a competitive advantage in delivering next-generation therapies to global markets.
- Key Takeaways:
- European AI regulations require careful navigation for US pharma companies.
- Understanding the layered regulatory framework is crucial for compliance.
- Engaging early with regulatory authorities can prevent delays.
- Establishing robust governance and compliance structures fosters smoother transitions.
- Proactive data management can leverage regulatory provisions for efficiency.
In summary, a strategic approach to Europe’s AI regulations can empower US pharma innovators to not only comply but also excel in a dynamic market landscape.
Read more → pharmaphorum.com